2 Minutes with Joey - HIMS Stock News

Avsnitt

• 
  HIMS Today - Aug 13: Earnings Miss and Caution 13.08.2026 1min

  Hey there! It’s your boy Joey, long-time investor here, breaking down today’s action. We're talking about Hims & Hers, and it was a bit of a red day—down about half a percent. Not a great look.So, what went down? Well, after their quarterly results dropped, the stock kinda trimmed its losses but still didn’t shake off the bad vibes. The earnings report wasn’t what folks were hoping for, and that really put a damper on things. Now, why the fuss? Basically, Wall Street’s feeling a little cautious. They’re worried that while Hims is seeing record subscriber growth, it’s not enough to cover the slide in margins. Yeah, that one stung. They posted a GAAP loss, and the gross margin took a hit too, which had investors hitting the sell button pretty quickly. On the flip side, Hims is gearing up for a launch of some new peptides, which could be exciting. But right now, the cautious outlook from analysts is kind of overshadowing that. So, just to wrap it up, Hims & Hers is navigating some choppy waters after that earnings miss, and while there’s some growth, it’s not all sunshine and rainbows. Remember, this is just for info and entertainment, not financial advice. Catch you later!
• 
  HIMS Today - Aug 12: Costly Weight-Loss Push 12.08.2026 1min

  Hey there! It’s Joey, your friendly investor buddy, here to break down what happened with Hims & Hers today. So, HIMS had a rough day, dropping about 2.8%. Ouch, right?Here’s the scoop: the stock took a hit today, and it’s kinda clear why. Hims & Hers reported some numbers that didn’t sit well with investors. They beat revenue expectations, which sounds good, but there was a major catch. Their profitability took a nosedive, mainly because of a pricey push into weight-loss products. Like, they tried to expand into this market, but it’s squeezing their margins hard. You know what that means? Less cash flow, and that’s never a good thing.People were definitely not vibing with the news. It seems like they were ready to hit that sell button fast once the details came out. Plus, there’s some ongoing legal risk hanging over their heads, which isn’t helping the mood at all. Investors are probably feeling a bit skittish about that too.One thing to keep in mind is that Hims & Hers is still trying to find its footing. They’re navigating some tricky waters with these losses, and it might take a bit for them to get back on stable ground. So, that’s something to watch for.Anyway, that’s the lowdown on HIMS today! Just remember, this is all for fun and info, not financial advice. Catch you later!
• 
  HIMS Today - Aug 11: Costly Weight-Loss Push Squeezes Margins 11.08.2026 1min

  Hey there, it’s Joey! I’ve been investing for years and I’m here to break down what went down with Hims & Hers today. So, HIMS had a rough one, closing down about 1.3%. Ouch.Now, here’s what happened. The stock got smoked after some not-so-great news. They reported a net loss for Q2, and it turns out their weight-loss initiative is costing them a pretty penny. Investors weren't feeling it, so they hit that sell button hard. The whole vibe around the stock turned sour real quick.As for why this happened, it's all about those rising expenses. Hims is pouring a lot of cash into their weight-loss products, and it's squeezing their margins. Like, they’re trying to get in on that trend, but it looks like it’s backfiring a bit. This move raised some eyebrows and made folks worried about their bottom line. When the numbers came out, it just confirmed those worries, and bam! Down goes the stock.Oh, and something to keep an eye on: Hims is still pushing their telehealth services and other products, which could be a bright spot down the line. They’ve got their hands in a lot of pots, so it’s not all doom and gloom.Alright, that’s the scoop for today. Just remember this is all info and entertainment, not financial advice. Catch you later!
• 
  HIMS Today - Aug 10: Earnings Report Anticipation 10.08.2026 1min

  Hey there! It’s Joey here, your friendly investor buddy, breaking down the day in the market for Hims & Hers, ticker HIMS. Today was a bit of a mixed bag, but overall, it ended up in the green, up about two percent. So, what went down? HIMS popped a little today, but honestly, it’s been a bit of a rollercoaster lately. There’s been a lot of chatter about their upcoming earnings report. Everybody's on edge, wondering if they can turn things around after missing estimates last quarter. Yeah, that one stung. Now, why the buzz? Well, Truist came out and reiterated their "Hold" rating on HIMS, setting a target at $27. That’s a bit lower than where it’s sitting now, so some folks might be scratching their heads. It seems like investors are weighing the potential for a rebound against that not-so-great past performance. Plus, the whole market's been feeling the heat from inflation data, which can mess with stock vibes, you know? And let’s not ignore that PPI report that dropped today. It’s affecting a bunch of stocks, including HIMS. Investors are trying to figure out how inflation will play into HIMS’s future. It’s like a puzzle that’s still missing a few pieces.One thing to keep in mind? The upcoming earnings report is definitely going to be a big deal. It could either be the spark they need or another bump in the road. So, to wrap it up, Hims & Hers had a decent day, but there’s a lot of uncertainty floating around with that earnings report coming up. Just remember, this is all for fun and information, not financial advice. Catch you later!
• 
  HIMS Today - Aug 09: FTC Suit and AI Weight-Loss Buzz 09.08.2026 1min

  Hey there! It's Joey, your go-to guy for stock talk. I've been investing for a long time, and today we're checking out Hims & Hers, or HIMS for short. It was a solid green day, up about 6.5%. Nice little bump, right?So, what’s the scoop? HIMS had a pretty good day today, and it seems like a lot of folks were excited about their new AI weight-loss program. Yeah, that’s right! They’re diving into the weight-loss game with some tech wizardry. That got people buzzing and hitting the buy button. Plus, there’s been some chatter about an FTC suit that didn’t seem to scare investors off. Instead, they took it as a sign that HIMS is still in the game and ready to roll.Now, why did the stock get this boost? Well, it looks like investors are feeling optimistic about HIMS’s new ventures. The AI weight-loss launch is seen as a potential game-changer. Everyone's looking to see if this can help them score big before their Q2 earnings drop. And yeah, there’s been some insider trading and hedge fund activity that has people wondering if the big players are making moves for a reason. It’s like a little drama unfolding, and we’re all here for it.Oh, and one thing to keep an eye on: earnings are coming up soon. That’s always a big deal. Investors are gonna be looking for any hints about how things are going, especially with all the buzz around that AI program.So, to wrap it up, HIMS had a nice day, fueled by some exciting new plans and a bit of market drama. Just remember, I’m here to share info and keep it fun, not to give you financial advice. Catch you later!
• 
  HIMS Today - Aug 08: Weight Loss Buzz Lifts Stock 08.08.2026 1min

  Hey there! It’s Joey here, your friendly investor buddy. I’ve been in the game for a while, and today we’re talking about Hims & Hers, which had a pretty solid day, climbing up about 6.5%. Not too shabby!So, what went down? HIMS saw some nice upward movement today, closing at $31.59. It’s like the stock just caught a bit of a breeze and took off. There was a lot of chatter about weight-loss products and how they might be boosting the company’s appeal. You know how it is—everyone’s trying to get a piece of that health and wellness pie, and HIMS is right in the mix.Now, why the hype? Well, it seems like folks are buzzing about the potential for weight-loss momentum to really lift HIMS before their Q2 earnings drop. Yeah, people are optimistic. Plus, some analysts think the stock is still undervalued even after a massive run-up—313% in the last little while. That’s a wild ride! There’s also the California State Teachers Retirement System getting in on the action, which always raises eyebrows. When big players like that start buying, it tends to get people talking.But hold up! Not everything is sunshine and rainbows. Citi pointed out a “big caveat” with Amazon’s push into the GLP-1 weight-loss drug space, suggesting it could pose some risks to HIMS’ business model. So, while the stock is up today, there’s a bit of a cloud hanging over the whole situation. Classic stock market drama, right?On the horizon, just a heads-up: HIMS has its Q2 earnings report coming up soon, and that’s always a big deal. Investors will be keeping a close eye on those numbers to see if the weight-loss buzz translates into solid sales.Alright, that’s a wrap! HIMS had a good day, and there’s some interesting stuff brewing. Just remember, I’m here to keep you informed and entertained, but this isn’t financial advice. Stay savvy out there!
• 
  HIMS Today - Aug 07: New Partners Fuel Push 07.08.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been around the block a few times, and today we’re talking about Hims & Hers, or HIMS for short. It was a pretty solid day for them, closing up about 2.9%. Not bad, right?So, what went down? The stock saw some nice movement today, and that’s always a good vibe. Investors seemed pretty optimistic, and the volume was right in line with what we usually see. So, no crazy spikes or drops, just steady action.Now, why the good energy? Well, it looks like HIMS is gearing up for a breakout week. They’ve announced eight new partnerships that are really pushing their all-in-one health platform concept. That’s a big deal! Analysts are even talking about a potential 20% upside in the long run. Sounds promising, huh? Plus, there’s chatter about HIMS eyeing a two-week green streak, which is always a good sign for momentum. But, hold up! There’s also some noise about the FTC suing Hims & Hers. Some folks are worried, but experts are saying not to panic. It seems like they think the company will handle it just fine. So, while that’s a bit of a cloud hanging over them, it doesn’t seem to be shaking investors too much today.Just a heads-up, HIMS is really focusing on expanding its services and offerings, which could be a game-changer in the health space. The more they can provide under one roof, the better for their growth potential.Alright, that’s a wrap for today! Just remember, I’m here to break it down for you, not to give any financial advice. Keep it chill and informed, my friends! Catch you later!
• 
  HIMS Today - Aug 06: Stock Declines Amid FTC Buzz 06.08.2026 1min

  Hey there, it’s Joey here! I’ve been investing for a while now, and I’m breaking down the day for you. Today, we’re talking about Hims & Hers, and it was a red day—down about 2.8%. Ouch!So, what went down? HIMS got smoked today. It started off with some buzz about a potential rally, but that didn’t really help. Instead, it just kinda drifted down. I mean, you know how it goes—sometimes stocks just can’t catch a break.Now, onto the why. One big reason for today’s dip is the ongoing FTC lawsuit against Hims & Hers. Yeah, that one stung. Even though some folks are saying not to panic, the news definitely put a bit of a damper on investor vibes. Plus, there’s chatter about an investigation into the company. That’s never a good look, right? It’s like when you’re at a party, and someone spills a drink—everyone just kind of stares. But here’s the kicker: there was also some buzz about a potential rally up to 60% this week. Sounds wild, huh? A fund manager mentioned that he wouldn’t be surprised if that happened, mainly due to some patch-up talk with Novo Nordisk. But honestly, that didn’t seem to lift HIMS today. It’s like a rollercoaster that just can’t decide whether to go up or down.Looking ahead, keep in mind that the FTC lawsuit is still looming over the stock. That’s definitely something to keep your eyes on. It’s like when you’re waiting for a text back from someone—it’s just hanging there, and you’re not sure how it’ll turn out.Alright, that’s a wrap for today! Just remember, this is all for fun and info, not financial advice. Always do your own homework before diving in. Catch you later!
• 
  HIMS Today - Aug 05: Stock Stumbles After Q1 Report 05.08.2026 1min

  Hey there! I’m Joey, your friendly neighborhood investor, and I’m here to break down what went down with Hims & Hers today. So, HIMS had a bit of a rough ride. It ended the day in the red, down about half a percent. Ouch!Now, here’s the scoop. The stock took a hit after a not-so-great Q1 report came out. Investors were probably expecting more, and when the numbers didn’t stack up, people hit the sell button real quick. It’s like when you order a pizza and it shows up with pineapple on it – not what you wanted, right? But it wasn’t all bad news. There’s chatter about potential deals with big players like Novo and Lilly, which has some folks saying HIMS could be the "Netflix of healthcare." That’s a pretty bold statement! It gives a glimmer of hope for the future, but right now, investors seem to be focused on the here and now, and that Q1 report isn’t helping.Also, the stock has been bouncing around a bit lately. After a rough patch, it did see a brief jump of 11% in after-hours trading, but that was short-lived and didn’t carry into today. It’s like a rollercoaster ride – thrilling but also a bit scary at times. One thing worth keeping an eye on is that there’s talk about HIMS being priced below its intrinsic value. That could mean there’s some potential for growth if they can turn things around. So, to wrap it all up, HIMS had a tough day following a not-so-great earnings report, but there’s some buzz about future deals that could change the game. Just remember, folks, I’m here to share info and keep it light, not to give you any financial advice. Thanks for hanging out with me today! Catch you next time!
• 
  HIMS Today - Aug 04: Stock Crashes Overnight 04.08.2026 1min

  Hey there! It’s Joey here, your friendly longtime investor, breaking down today’s stock action. Today, we’re talking about Hims & Hers, and it was a rough day, folks. The stock got smoked, dropping about 1.5%. Ouch.So, what went down? Well, HIMS had a brutal Q1, and that really shook investors. The stock crashed overnight after the earnings report hit, and people were not happy. You could feel the panic as the sell button got hit fast. It’s like a bad breakup, you know? Nobody wants to stick around after that kind of news.Now, why did this happen? There’s a lot of chatter about the company facing serious legal issues, and analysts are saying there's “very high” uncertainty around it. Some even think HIMS doesn’t have a “moat,” which is fancy talk for saying they don’t have a strong competitive advantage. That’s a tough spot to be in. And then there are those whispers about competition from big players like Novo and Lilly. One investor even went as far as calling HIMS the “Netflix of healthcare.” That’s a pretty bold claim, considering the mess they’re in right now.Looking ahead, there’s some buzz about their earnings report coming up on August 10. Some folks are saying the stock could swing as much as 14% after that. So, keep your eyes peeled for that. Anyway, today was definitely a bumpy ride for Hims & Hers. Just remember, I’m here to share info and keep it real, not to give you financial advice. Take care out there, and catch you later!
• 
  HIMS Today - Aug 03: FTC Lawsuit and Amazon News 03.08.2026 1min

  Hey there! It’s Joey, your friendly stock enthusiast, here to break down what went down with Hims & Hers today. The stock had a rough ride and ended up in the red, dropping about 8.5%. Yeah, that one stung.So, here’s the scoop. Hims started off strong, but then things took a turn. The buzz around Amazon ramping up its game in the GLP-1 market got everyone a bit jittery. With all the noise about Ozempic and competition heating up, investors didn’t like what they saw. Also, news came out that Hims is under fire for sharing sensitive data with third parties, and the FTC isn’t happy about it. That definitely didn’t help the stock's vibes today.Now, let's talk about why this happened. The Amazon news is big because it’s all about the future of weight loss drugs, and when a giant like Amazon gets involved, it can shift the whole market. Investors are worried that competition could hurt Hims’ growth. Plus, the FTC situation is like a cloud hanging over the company. When you mix regulatory drama with fierce competition, it’s a recipe for a sell-off. People hit that sell button fast, and the stock took a hit.Looking ahead, Hims is gearing up for earnings reports soon, so that’ll be something to keep an eye on. Earnings can always shake things up, and with everything going on, it’ll be interesting to see how they spin the data.So, to wrap it up, Hims & Hers had a tough day, mainly thanks to some serious competition vibes from Amazon and the FTC drama. Just remember, this is all for fun and info, not financial advice. Catch you later!
• 
  HIMS Today - Aug 02: FTC Lawsuit Raises Concerns 02.08.2026 1min

  Hey there, it’s Joey! I’ve been investing for years, and today I’m breaking down Hims & Hers, or HIMS for short. So, it was a red day for the stock, down about 2.7%. Ouch.So, what happened? The stock took a hit after some news dropped. It seems there’s a lawsuit from the FTC that’s got folks worried about the valuation of the company. Yeah, that one stung. When the FTC gets involved, you know it’s serious business. Investors are getting jittery, and it seems like some people are hitting that sell button pretty fast.Now, why the drama? Well, the lawsuit is raising fresh questions about how Hims & Hers is valued in the market. It’s like when your favorite restaurant gets a bad review, and suddenly you’re not so sure about grabbing dinner there. The FTC is looking into some practices, and that uncertainty has definitely put a damper on the stock today. Some folks are even comparing this situation to the brutal Q1 that left investors feeling uneasy. But there’s a glimmer of hope, as some are saying that partnerships with companies like Novo and Lilly could turn Hims into the “Netflix of healthcare.” Sounds ambitious, right?And here’s something else to keep in mind: the market’s been buzzing about inflation data lately, which could be affecting HIMS along with other stocks. So yeah, there’s a lot going on in the background.To wrap it up, Hims & Hers had a rough day, mostly thanks to that FTC lawsuit stirring up worries about its valuation. But, there’s still some chatter about potential partnerships that could turn things around in the long run. Remember, I’m just here to give you the info and keep it casual, not to give any financial advice. Catch you later!
• 
  HIMS Today - Aug 01: Stock Rebounds After Short Bets Burned 01.08.2026 1min

  Hey, what’s up? It’s Joey here, your friendly investor buddy, breaking down the day in stocks. Today, we’re talking about Hims & Hers, and it was a green day—up about 2.7%. Not too shabby!So, what happened? Well, HIMS had a nice little rebound today. After some rough patches, it bounced back, catching some eyes. The stock was buzzing, and folks were feeling optimistic. Volume was pretty steady, which means people were interested in trading it.Now, why did this happen? Apparently, there’s been a lot of chatter about a deal with Novo Nordisk that sent the stock soaring. Sounds like some short bets got totally smoked, burning through $546 million. Yeah, that one stung! Investors were clearly reacting to this news, and it seems like they’re seeing some potential with HIMS moving forward. There’s also this FTC lawsuit hanging over them, which could change the game for how people view the company's business practices. That’s definitely adding some drama to the mix.And just so you know, there’s talk that HIMS is still undervalued and could have some serious upside. Some analysts are saying it might be a good time to pay attention. But hey, no pressure, right? Just something to keep in mind.Alright, that wraps it up for today! Just remember, I’m here to give you the lowdown, not financial advice. Stay chill and keep doing your thing!
• 
  HIMS Today - Jul 31: FTC Sues Hims & Hers 31.07.2026 1min

  Hey there! It’s Joey, your go-to guy for stock chat. I’ve been investing for a while now, and today we’re talking about Hims & Hers. Spoiler alert: it was a rough day. The stock dipped about 10%. Ouch.So, what went down? Well, the big news is that the FTC decided to sue Hims & Hers over some serious issues related to their data and billing practices. Yeah, that one stung. The lawsuit claims they were sharing user health info with companies like Meta and Snap. Not cool, right? People didn’t take that news lightly, and you could see it in the stock price. Investors were hitting the sell button like it was going out of style.Now, why did this happen? The FTC is basically saying Hims & Hers didn't handle customer data properly. It’s a big deal when a company is accused of not protecting sensitive information. That kind of news tends to freak people out. The stock market hates uncertainty, and this lawsuit definitely adds a layer of it. Some folks are wondering if this could impact the company’s future growth or reputation. On the flip side, there are some articles out there saying Hims & Hers is still undervalued and has potential. But when you hear something like “lawsuit,” it tends to overshadow that kind of talk. Investors are all about risk assessment, and this lawsuit just raised the stakes a bit.One thing to keep an eye on is how Hims & Hers responds to this lawsuit. Their next moves could be crucial. If they handle it well, maybe they can bounce back. But if it drags on or gets messy, it could be a long road ahead.So, yeah, it’s definitely a day to keep your eyes peeled. Remember, I’m just here chatting about the news and what it means, not giving any financial advice. Keep it chill and informed, my friends! Until next time, catch you later!
• 
  HIMS Today - Jul 30: FTC Lawsuit Hits Hard 30.07.2026 1min

  Hey there! It's Joey, your friendly investor buddy here to break down what went down with Hims & Hers today. So, HIMS had a rough one — it got smoked, falling about 10%. Yeah, that one stung.So, here’s the scoop: the stock took a dive after news dropped that the FTC is suing them. Apparently, they’re in hot water for, get this, allegedly sharing user health info with Meta and Snap. Not a great look, right? Investors weren’t feeling it and hit the sell button fast. The market reacted like it was a horror movie, and nobody wanted to stick around to see what happens next.Now, why did this happen? Well, the FTC claims that Hims & Hers didn’t handle user data responsibly, which is a big deal in today’s world where privacy is everything. People are super sensitive about their health info, and if they think a company is mishandling it, they’re out. The lawsuit’s got folks worried about potential fines and what it could mean for Hims & Hers moving forward. It’s like they opened a can of worms, and now it’s all over the place.On the horizon, there’s chatter about the stock price target being cut to around $30.15. So, yeah, it implies some upside, but with all this FTC drama, who knows? Just a heads up if you’re keeping tabs on it.Alright, that’s the lowdown for today. Remember, I’m just here to keep you informed and entertained. This isn’t financial advice, so do your own homework. Catch you later!
• 
  HIMS Today - Jul 29: Stock Takes a Hit 29.07.2026 1min

  Hey, what’s up? It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today, we’re talking about Hims & Hers, or HIMS for short. It was a rough day, folks. The stock dropped about 5%. Ouch.So, what went down? HIMS got smoked today, closing at $27.86. Even with the broader market doing its thing, HIMS just couldn’t catch a break. It was like everyone hit the sell button at once. And yeah, that one stung a bit if you were holding on.Now, let’s chat about why this happened. There’s a lot going on in the background. First off, even though there’s some hype around certain stocks lately, HIMS didn’t ride that wave. There were reports about Bank of America dropping a warning regarding GLP-1 drugs, which are kinda key in the health space. That probably made some investors a little jittery. But here’s the kicker—despite the drop, there’s some optimism. The former CFO of Netflix is actually buying the dip. So, while some are running for the hills, others see potential.Oh, and here’s something to keep an eye on—BlackRock just disclosed it has an 11.9% stake in HIMS. That’s a pretty big deal, considering BlackRock is one of the biggest players out there. It shows there’s still some serious interest in the company.So, yeah, it was a tough day for HIMS. But there are still reasons to stay curious about what’s next. Just remember, I’m here to share info, not to give financial advice. Keep it chill, and I’ll catch you later!
• 
  HIMS Today - Jul 28: Short Bets Burned 28.07.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today we’re talking about Hims & Hers, or HIMS for short. It was a red day for them, down about 8%—yikes!So, what happened? Well, it looks like HIMS got smoked today. After a big run-up recently, they took a hit. The stock was riding high on some buzz about their potential in the peptide market, especially after an FDA panel gave a thumbs up to most of their compounds. But then, bam! Rival telehealth company Ro decided to slash prices on their GLP-1 subscriptions. That definitely shook things up and made folks hit the sell button fast.Now, why did this happen? It seems like investors were feeling the heat from the competition. HIMS had a fantastic day not too long ago, burning through a mountain of short bets after some big news from Novo Nordisk. But with Ro making aggressive moves, it threw a wrench in the works. Investors might’ve been worried about how that would impact HIMS's market share. It’s like a game of musical chairs, and right now, it feels like HIMS was left standing.One thing worth keeping an eye on is how HIMS plans to respond to this pricing war. They’ve got some promising stuff in the pipeline, but competition is fierce. If they can figure out a way to stand out, it might change the game again.So there you have it! HIMS had a rough ride today thanks to some serious competition. Remember, this isn’t financial advice—just me sharing what’s going on in the market. Stay curious, my friends, and catch you next time!
• 
  HIMS Today - Jul 27: FDA Panel Sparks Interest 27.07.2026 1min

  Hey there, it’s Joey! I’ve been investing for years and I’m here to break down what went down today with Hims & Hers, or HIMS for short. It was a green day, up about 3.76%. Not too shabby! So, what happened? HIMS had a bit of a wild ride today. After a rough Q1, where things looked pretty bleak, the stock actually saw some love. Retail traders are buzzing about some FDA news regarding peptides. They gave a thumbs up to six out of seven compounds, and that got people excited. So yeah, the stock popped a bit today as folks started betting on the potential upside. Now, why did it bounce back? Well, after that brutal first quarter, investors were pretty skittish. But then news of those FDA approvals came out, and suddenly, people started thinking, “Hey, maybe this company has some potential after all.” Some even compared HIMS to Netflix in the healthcare space, which is a pretty big deal if you ask me. Like, if they can pull that off, we might be looking at something special here.On the horizon, there’s chatter about how the ex-CFO of Netflix is buying into HIMS. That’s a strong signal. Even with some warnings from Bank of America about their GLP-1 drugs, this guy sees a bargain. When you have big names backing you, it tends to catch some eyes.So, to wrap it up, HIMS had a solid day, thanks to that FDA panel getting people hyped about peptides. It’s all about that potential right now. Just remember, this is all for your info and entertainment, not financial advice. Keep it chill, and I’ll catch you later!
• 
  HIMS Today - Jul 26: FDA Snubs Peptide 26.07.2026 1min

  Hey there! It’s Joey, your friendly neighborhood investor, and I’m here to break down what went down today with Hims & Hers, or HIMS for short. Spoiler alert: it was a rough day, and the stock got smoked, dropping about 14%. Ouch!So, what happened? Well, HIMS took a big hit today, and it’s all about the FDA. They just decided to give Hims & Hers' first peptide the cold shoulder, and that really shook things up. People were expecting some good news, but instead, they got a big fat no. That’s never a fun surprise, right? Now, why did this happen? The FDA advisory panel was supposed to have HIMS’ back, but clearly, they didn’t see it that way. Investors were hoping for a green light, thinking this peptide could be a game changer for the company. But when the news hit that it was getting rejected, folks didn’t waste any time hitting the sell button. It’s like they all got the same text at once saying, “Run!” and that’s exactly what they did.Looking ahead, there's chatter about how this decision could affect the company’s future. Some analysts are still throwing around the idea that HIMS might be undervalued, but it’s hard to see that from today's bloodbath. To wrap it all up, today was a tough one for HIMS. The FDA’s decision really stung, and investors are feeling it. Just remember, this recap is just for fun and info, not financial advice. Catch you later!
• 
  HIMS Today - Jul 25: FDA Panel Drama 25.07.2026 1min

  Hey there! It’s Joey, your friendly stock enthusiast, here to break down what happened with Hims & Hers today. So, HIMS? Yeah, it got smoked, down about 14% today. Ouch!So, what went down? The stock was riding high earlier when an FDA panel gave a thumbs-up to some peptide treatments, which had investors buzzing. But then, things took a nosedive. A lot of folks hit the sell button fast after hearing that the FDA advisors snubbed one of HIMS' key peptides. That one stung, for sure.Now, why did this happen? Well, the FDA's decision was a double-edged sword. On one hand, the panel backing some peptides gave hope that Hims & Hers could expand its offerings. But on the other hand, the rejection of a specific peptide put a damper on things. Plus, Amazon is stepping up its game in the GLP-1 market, which is creating a lot of noise and competition. Investors are worried about how this will affect HIMS moving forward, especially with earnings around the corner. So, yeah, there’s a lot of uncertainty swirling.Looking ahead, it’s worth knowing that Hims & Hers is still in the spotlight with the FDA’s ongoing discussions about peptides. If they loosen restrictions, it could open up some new doors for the company. But with the way today went, they’ve got some work to do to regain that confidence.Alright, that’s the scoop for today! Just remember, this is all for fun and info, not financial advice. Catch you later!